A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine—Morphine ARER | Zendy

Lynn R. Webster | Zendy; Carmela Pantaleon | Zendy; Manish S. Shah | Zendy; Ray DiFalco | Zendy; Matthew Iverson | Zendy; Michael D. Smith | Zendy; Eric R. Kinzler | Zendy; Stefan Aigner | Zendy

Open Access

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine—Morphine ARER

Author(s) -

Lynn R. Webster,

Carmela Pantaleon,

Manish S. Shah,

Ray DiFalco,

Matthew Iverson,

Michael D. Smith,

Eric R. Kinzler,

Stefan Aigner

Publication year - 2016

Publication title -

pain medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.893

H-Index - 97

eISSN - 1526-4637

pISSN - 1526-2375

DOI - 10.1093/pm/pnw213

Subject(s) - morphine , medicine , nasal administration , placebo , opioid , drug , anesthesia , adverse effect , pharmacology , alternative medicine , receptor , pathology

Misuse and abuse of prescription opioids remains a major healthcare concern despite considerable efforts to increase public awareness. Abuse-deterrent formulations of prescription opioids are designed to reduce intentional misuse, abuse, and prescription opioid-related death. A novel extended-release (ER) formulation of morphine (Morphine ARER; MorphaBond™) resists physical manipulation and retains the drug's ER characteristics, even if attempts are made to manipulate the formulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research